IDEXX Shares Surge on Strong Pet Diagnostics Demand and Upgraded Outlook
Idexx Laboratories benefited from the 2020 puppy boom, surpassing second-quarter expectations with $1.11 billion in sales and an adjusted $3.63 per share, driven by new products and resilient pet health market trends. The company raised its full-year sales outlook and saw its stock rise over 50% since April, reflecting investor confidence in its growth prospects despite industry challenges.